A $50 million Project NextGen competition to advance microneedle patch-based RNA vaccines.
BARDA calls on vaccine developers and patch makers to partner and accelerate new vaccine technologies.
BARDA calls on vaccine developers and patch makers to partner and accelerate new vaccine technologies.
The Patch Forward Prize, part of Project NextGen, is a $50 million competition to advance microneedle patch-based RNA vaccines for COVID-19, seasonal influenza, and pandemic influenza. The Biomedical Advanced Research and Development Authority (BARDA) calls on vaccine developers and patch makers to partner and accelerate new vaccine technologies.
The prize consists of three independent stages. The Concept Stage invited concept papers from all eligible entrants.
The Patch Forward Prize will award $50 million across three stages. The Concept Stage awarded $8 million to four winners. Each winning Concept Stage team received $2 million. The Preclinical Stage will award up to three winners $7 million each, and the Clinical Stage will award up to two winners $10.5 million each.
Access resources to learn more about patch-based RNA vaccine development, including the technologies, product development, and regulatory requirements.